Your browser doesn't support javascript.
loading
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles, Alasdair J; Twyman, Cary L; Arnold, Douglas L; Cohen, Jeffrey A; Confavreux, Christian; Fox, Edward J; Hartung, Hans-Peter; Havrdova, Eva; Selmaj, Krzysztof W; Weiner, Howard L; Miller, Tamara; Fisher, Elizabeth; Sandbrink, Rupert; Lake, Stephen L; Margolin, David H; Oyuela, Pedro; Panzara, Michael A; Compston, D Alastair S.
Affiliation
  • Coles AJ; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK. ajc1020@medschl.cam.ac.uk
Lancet ; 380(9856): 1829-39, 2012 Nov 24.
Article in En | MEDLINE | ID: mdl-23122650
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peptides / Adjuvants, Immunologic / Multiple Sclerosis, Relapsing-Remitting / Antibodies, Monoclonal, Humanized / Immunosuppressive Agents Type of study: Clinical_trials / Prognostic_studies Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: Lancet Year: 2012 Type: Article Affiliation country: United kingdom
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peptides / Adjuvants, Immunologic / Multiple Sclerosis, Relapsing-Remitting / Antibodies, Monoclonal, Humanized / Immunosuppressive Agents Type of study: Clinical_trials / Prognostic_studies Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: Lancet Year: 2012 Type: Article Affiliation country: United kingdom